Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and Ad-CEA in mCRC
NCT03050814Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2017
- Primary completion
- Aug 2021
- Modality
- Prophylactic Vaccines, Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab, Ad5-CEA vaccine in metastatic colorectal cancer (mCRC), sponsored by National Cancer Institute. Started Apr 2017; status: terminated.
02
Drugs
avelumabAd5-CEA vaccine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03050814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03050814.